Antitumor effects of anti-CD40/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model

International Immunopharmacology

Volumn 17, Issue 4, 2013, Pages 1141-1147

  Qu, Xiaoyi ^a   Felder, Mildred A R ^a   Perez Horta, Zulmarie ^a   Sondel, Paul M ^a,b   Rakhmilevich, Alexander L ^a,b  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

5 Fluorouracil; Anti CD40; CpG; Gemcitabine; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CD40 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; FLUOROURACIL; GEMCITABINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MELANOMA B16; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PERITONEAL CAVITY; PHENOTYPE; PRIORITY JOURNAL; SUPPRESSOR CELL; TUMOR VOLUME;

5-FLUOROURACIL; ANTI-CD40; CPG; GEMCITABINE; IMMUNOTHERAPY;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, CD40; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CELL LINE, TUMOR; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; IMMUNOTHERAPY; MACROPHAGES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NITRITES; OLIGODEOXYRIBONUCLEOTIDES; SKIN NEOPLASMS; TUMOR BURDEN;

EID: 84887279542     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2013.10.019     Document Type: Article

References (30)

1. M.S. Mitchell Combinations of anticancer drugs and immunotherapy Cancer Immunol Immunother 52 2003 686 692 (Pubitemid 37363639)
2. R.J. North Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells J Exp Med 155 1982 1063 1074 (Pubitemid 12142723)
3. + T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide Blood 105 2005 2862 2868 (Pubitemid 40446280)
4. E.F. Solomayer, M. Feuerer, L. Bai, V. Umansky, P. Beckhove, and G.C. Meyberg Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer Clin Cancer Res 9 2003 174 180 (Pubitemid 36109730)
5. E. Fonsatti, M. Maio, M. Altomonte, and P. Hersey Biology and clinical application of CD40 in cancer treatment Semin Oncol 37 2010 517 523
6. A. Khong, D.J. Nelson, A.K. Nowak, R.A. Lake, and B.W. Robinson The use of agonistic anti-CD40 therapy in treatments for cancer Int Rev Immunol 31 2012 246 266
7. A.L. Rakhmilevich, K.L. Alderson, and P.M. Sondel T cell-independent antitumor effects of CD40 ligation Int Rev Immunol 31 2012 267 278
8. R.H. Vonderheide, K.T. Flaherty, M. Khalil, M.S. Stumacher, D.L. Bajor, and N.A. Hutnick Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody J Clin Oncol 25 2007 876 883 (Pubitemid 350002889)
9. R. Advani, A. Forero-Torres, R.R. Furman, J.D. Rosenblatt, A. Younes, and H. Ren Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma J Clin Oncol 27 2009 4371 4377
10. M. Hussein, J.R. Berenson, R. Niesvizky, N. Munshi, J. Matous, and R. Sobecks A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma Haematologica 95 2010 845 848
11. G.L. Beatty, E.G. Chiorean, M.P. Fishman, B. Saboury, U.R. Teitelbaum, and W. Sun CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans Science 331 2011 1612 1616
12. I.N. Buhtoiarov, H. Lum, G. Berke, D. Paulnock, P.M. Sondel, and A.L. Rakhmilevich CD40 ligation induces antitumor reactivity of murine macrophages via an IFN gamma-dependent mechanism J Immunol 174 2005 6013 6022 (Pubitemid 40663788)
13. I.N. Buhtoiarov, H.D. Lum, G. Berke, P.M. Sondel, and A.L. Rakhmilevich Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects J Immunol 176 2006 309 318 (Pubitemid 43023276)
14. E.E. Johnson, I.N. Buhtoiarov, M.J. Baldeshwiler, M.A. Felder, N. Van Rooijen, and P.M. Sondel Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice J Immunother 34 2011 76 84
15. I.N. Buhtoiarov, P.M. Sondel, J.M. Wigginton, T.N. Buhtoiarova, E.M. Yanke, and D.A. Mahvi Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages Immunology 132 2011 226 239
16. H.D. Lum, I.N. Buhtoiarov, G. Berke, D.M. Paulnock, P.M. Sondel, and A.L. Rakhmilevich In vivo CD40 ligation can induce T cell-independent antitumor effects that involve macrophages J Leukoc Biol 79 2006 1181 1192 (Pubitemid 44835552)
17. A.L. Rakhmilevich, M.J. Baldeshwiler, T.J. Van De Voort, M.A. Felder, R.K. Yang, and N.A. Kalogriopoulos Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects Cancer Immunol Immunother 61 2012 1683 1697
18. H.K. Le, L. Graham, E. Cha, J.K. Morales, M.H. Manjili, and H.D. Bear Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice Int Immunopharmacol 9 2009 900 909
19. J. Vincent, G. Mignot, F. Chalmin, S. Ladoire, M. Bruchard, and A. Chevriaux 5-Fluoruracil selectively kills tumor-associated myeloid- derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity Cancer Res 70 2010 3052 3061
20. D.I. Gabrilovich, and S. Nagaraj Myeloid-derived suppressor cells as regulators of the immune system Nat Rev 9 2009 162 174
21. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity Clin Cancer Res 11 2005 6713 6721 (Pubitemid 41339014)
22. A.L. Rakhmilevich Neutrophils are essential for resolution of primary and secondary infection with Listeria monocytogenes J Leukoc Biol 57 1995 827 831
23. J.M. Daley, A.A. Thomay, M.D. Connolly, J.S. Reichner, and J.E. Albina Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice J Leukoc Biol 83 2008 64 70
24. C. Fortin, X. Huang, and Y. Yang NK cell response to vaccinia virus is regulated by myeloid-derived suppressor cells J Immunol 189 2012 1843 1849
25. T. Zhang, and D. Herlyn Combination of active specific immunotherapy or adoptive antibody or lymphocyte immunotherapy with chemotherapy in the treatment of cancer Cancer Immunol Immunother 58 2009 475 492
26. F. Moschella, E. Proietti, I. Capone, and F. Belardelli Combination strategies for enhancing the efficacy of immunotherapy in cancer patients Ann N Y Acad Sci 1194 2010 169 178
27. H.D. Lum, I.N. Buhtoiarov, B.E. Schmidt, G. Berke, D.M. Paulnock, and P.M. Sondel Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumor-necrosis factor-α Immunology 118 2006 261 270 (Pubitemid 43727432)
28. P. Sinha, V.K. Clements, S.K. Bunt, S.M. Albelda, and S. Ostrand-Rosenberg Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response J Immunol 179 2007 977 983
29. C.M. Diaz-Montero, M.L. Salem, M.I. Nishimura, E. Garrett-Mayer, D.J. Cole, and A.J. Montero Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy Cancer Immunol Immunother 58 2009 49 59
30. A.M. Hicks, G. Riedlinger, M.C. Willingham, M.A. Alexander-Miller, C. Von Kap-Herr, and M.J. Pettenati Transferable anticancer innate immunity in spontaneous regression/complete resistance mice Proc Natl Acad Sci U S A 103 2006 7753 7758